Bioxyne extends its footprint to Indonesia as it acquires majority ownership in an Indonesian sales company

bio technology

Today morning, 26 September 2018, Bioxyne Limited announced the acquisition of 95% holdings in the Indonesian Direct Selling Company P.T. Gamat Utama (PTG) for an up-front purchase consideration of $121,000. The seller PTG continues to hold back 5% interest in the company.

In addition to the cost of takeover, Bioxyne is reportedly liable to pay further $44,000 if the revenue from ‘existing’ sales exceeds $450,000 in a year falling next to the date of acquisition.

Seller PTG holds a direct sales license in Indonesia, acquired in 2015. It is into distribution business of health products and supplements with 2,500 members.

Bioxyne told investors that Indonesia’s direct selling market which attracts a value of US$1 billion and plus gives a massive growth opportunity to Bioxyne’s consumer dietary supplements and its other health and wellness products.

The acquisition marks a key geographical expansion of Bioxyne’s business which provides a new distribution channel to penetrate into Indonesian market while seizing an advantage over economies of scale in New Zealand’s distribution and production facilities.

CEO of Bioxyne Limited N H Chua stated that the acquisition of Indonesian P.T. Gamat Utama was a stepping stone in the company’s Asian Distribution strategy. He added that the company continues to establish and develop Bioxyne’s business in other significant Asian markets. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Further, BXN’s announcement informed that Bioxyne needs to capitalize the Indonesian company up to $900,000 in order to adhere with Indonesian foreign investment PT PMA regulations.

Last year Bioxyne inked an acquisition deal with AVSA international to allow the sale of its products in Thailand, Myanmar, Cambodia, Philippines and Mauritius.

Despite announcing the expansion into Asian market, Bioxyne witnessed a heavy downfall in its share price. BXN’s stock fell by 5.128% to $0.037 on 26 September 2018 (6:03 PM AEST). The stock has seen a performance change of 44.44% over the past one year but the change has turned to negative 26.42% in the last three months.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report